Lexeo rises on alignment with FDA on development plan for gene therapy
13/11/2024 14:28
** Shares of gene therapy developer Lexeo Therapeutics
LXEO.O rise 13.62% to $8.74 premarket
** Co says reached alignment with FDA on registrational
development plan for LX2006 to support an accelerated approval
pathway
** LX2006 is being developed as a gene therapy that is
delivered intravenously for the treatment of Friedreich's ataxia
cardiomyopathy
** Friedreich's ataxia is a genetic multi-system disorder
and 80% of patients are estimated to develop cardiomyopathy, a
type of heart disease
** LX2006 was granted regenerative medicine advanced therapy
(RMAT) designation to accelerate development - LXEO
** Brokerage Stifel says alignment is a big win
** Up to last close, stock down ~42% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Recent news on Lexeo Therapeutics
See all newsBrief: Lexeo Therapeutics Enters Into Agreement To Acquire Mantle Therapeutics And Announces Multiple New Strategic Collaborations To Expand Leadership In Friedreich Ataxia
Brief: Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Lx2020
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
U.S. STOCKS ON THE MOVE-Datadog, Terawulf
Lexeo rises as co sets late-stage trial plan for gene therapy in rare heart disease